Merck Arcoxia MEDAL Results Will Likely Not Meet FDA Gold Standard

Despite the release of positive results from a long-term cardiovascular safety trial of its Vioxx follow-on Arcoxia, Merck will likely need to conduct additional studies before receiving FDA approval of the COX-2 inhibitor